• LAST PRICE
    45.4350
  • TODAY'S CHANGE (%)
    Trending Down-0.3950 (-0.8619%)
  • Bid / Lots
    45.3500/ 8
  • Ask / Lots
    45.5200/ 8
  • Open / Previous Close
    45.3300 / 45.8300
  • Day Range
    Low 44.9100
    High 45.7681
  • 52 Week Range
    Low 7.6000
    High 59.2300
  • Volume
    42,039
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Monday's close: 45.83
TimeVolumeHROW
09:32 ET719645.33
09:33 ET164045.325
09:35 ET10045.375
09:37 ET120045.53
09:39 ET20045.53
09:42 ET228545.6387
09:44 ET117145.363673
09:46 ET182145.4
09:48 ET51045.495
09:50 ET80645.3772
09:51 ET110045.25
09:53 ET20045.31
09:55 ET831345.07
09:57 ET10045.165
10:00 ET203644.925
10:02 ET120945.015
10:04 ET130045.085
10:06 ET140745.435
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesHROW
Harrow Inc
1.6B
-47.8x
---
United StatesLGND
Ligand Pharmaceuticals Inc
2.0B
49.2x
-12.71%
United StatesOCUL
Ocular Therapeutix Inc
1.6B
-9.4x
---
United StatesIMCR
Immunocore Holdings PLC
1.6B
-28.5x
---
United StatesAVDL
Avadel Pharmaceuticals PLC
1.4B
-12.6x
---
United StatesEOLS
Evolus Inc
1.0B
-18.1x
---
As of 2024-11-05

Company Information

Harrow, Inc. is an eyecare pharmaceutical company. The Company is engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the United States market. It provides a comprehensive portfolio of prescription and non-prescription pharmaceutical products. It owns commercial rights to portfolios of branded ophthalmic pharmaceutical products in North America, all of which are marketed under the Harrow name. It owns and operates ImprimisRx, an ophthalmology-focused pharmaceutical-compounding business. It owns United States commercial rights to various products: IHEEZO, VEVYE, TRIESENCE, VIGAMOX, ILEVRO, FLAREX, NATACYN, ZERVIATE and others. VIGAMOX (moxifloxacin hydrochloride ophthalmic solution) 0.5%, a fluoroquinolone antibiotic eye drops for the treatment of bacterial conjunctivitis caused by susceptible strains of organisms. IHEEZO (chloroprocaine hydrochloride ophthalmic gel) 3% is a low-viscosity gel indicated for ocular surface anesthesia.

Contact Information

Headquarters
102 WOODMONT BLVD, SUITE 610NASHVILLE, TN, United States 37215
Phone
615-733-4731
Fax
858-345-1745

Executives

Chairman of the Board, Chief Executive Officer
Mark Baum
Chief Financial Officer, Corporate Secretary
Andrew Boll
President and Chief Executive Officer of ImprimisRx, Chief Commercial Officer
John Saharek
Lead Independent Director
Perry Sternberg
Independent Director
Adrienne Graves

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$1.6B
Revenue (TTM)
$154.1M
Shares Outstanding
35.5M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
0.74
EPS
$-0.95
Book Value
$2.01
P/E Ratio
-47.8x
Price/Sales (TTM)
10.5
Price/Cash Flow (TTM)
---
Operating Margin
-5.53%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.